For the year ending 2025-12-31, THC had -$136M decrease in cash & cash equivalents over the period. $2,530M in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 2,367 |
| Depreciation and amortization | 863 |
| Deferred income tax expense (benefit) | 9 |
| Stock-based compensation expense | 104 |
| Impairment and restructuring charges, and acquisition-related costs | 130 |
| Litigation and investigation costs | -64 |
| Net losses (gains) on sales, consolidation and deconsolidation of facilities | -1 |
| Loss from early extinguishment of debt | -4 |
| Equity in earnings of unconsolidated affiliates, net of distributions received | 34 |
| Amortization of debt discount and debt issuance costs | 23 |
| Net gains from the sale of investments and long-lived assets | 4 |
| Other items, net | 6 |
| Accounts receivable | -20 |
| Inventories and other current assets | 73 |
| Income taxes | 25 |
| Accounts payable, accrued expenses and other current liabilities | 209 |
| Other long-term liabilities | 9 |
| Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements | 121 |
| Net cash provided by operating activities | 3,540 |
| Purchases of property and equipment | 1,010 |
| Purchases of businesses or joint venture interests, net of cash acquired | 308 |
| Proceeds from sales of facilities and other assets | 38 |
| Proceeds from sales of marketable securities and long-term investments | 93 |
| Purchases of marketable securities and long-term investments | 90 |
| Other items, net | -2 |
| Net cash provided by (used in) investing activities | -1,275 |
| Repayments of borrowings | 2,372 |
| Proceeds from borrowings | 2,276 |
| Repurchases of common stock | 1,386 |
| Debt issuance costs | 32 |
| Distributions paid to noncontrolling interests | 809 |
| Proceeds from the sale of noncontrolling interests | 42 |
| Purchases of noncontrolling interests | 92 |
| Advances from managed care payers | 0 |
| Repayments of advances from managed care payers | 32 |
| Taxes paid related to net share settlement, net of proceeds from shares issued under stock-based compensation plans | 51 |
| Other items, net | 55 |
| Net cash used in financing activities | -2,401 |
| Net increase (decrease) in cash and cash equivalents | -136 |
| Cash and cash equivalents at beginning of period | 3,019 |
| Cash and cash equivalents at end of period | 2,883 |
TENET HEALTHCARE CORP (THC)
TENET HEALTHCARE CORP (THC)